|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPRTN |
Gene summary for SPRTN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPRTN | Gene ID | 83932 |
| Gene name | SprT-like N-terminal domain | |
| Gene Alias | C1orf124 | |
| Cytomap | 1q42.2 | |
| Gene Type | protein-coding | GO ID | GO:0000731 | UniProtAcc | Q9H040 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83932 | SPRTN | LZE2T | Human | Esophagus | ESCC | 4.41e-02 | 4.04e-01 | 0.082 |
| 83932 | SPRTN | LZE4T | Human | Esophagus | ESCC | 8.42e-04 | 1.41e-01 | 0.0811 |
| 83932 | SPRTN | LZE7T | Human | Esophagus | ESCC | 1.20e-08 | 4.00e-01 | 0.0667 |
| 83932 | SPRTN | LZE24T | Human | Esophagus | ESCC | 7.29e-10 | 2.62e-01 | 0.0596 |
| 83932 | SPRTN | LZE21T | Human | Esophagus | ESCC | 3.90e-02 | 1.45e-01 | 0.0655 |
| 83932 | SPRTN | P1T-E | Human | Esophagus | ESCC | 3.65e-04 | 3.20e-01 | 0.0875 |
| 83932 | SPRTN | P2T-E | Human | Esophagus | ESCC | 5.88e-23 | 3.87e-01 | 0.1177 |
| 83932 | SPRTN | P4T-E | Human | Esophagus | ESCC | 1.79e-12 | 2.66e-01 | 0.1323 |
| 83932 | SPRTN | P5T-E | Human | Esophagus | ESCC | 3.47e-13 | 2.95e-01 | 0.1327 |
| 83932 | SPRTN | P8T-E | Human | Esophagus | ESCC | 1.99e-10 | 1.28e-01 | 0.0889 |
| 83932 | SPRTN | P9T-E | Human | Esophagus | ESCC | 1.61e-12 | 2.59e-01 | 0.1131 |
| 83932 | SPRTN | P10T-E | Human | Esophagus | ESCC | 5.85e-26 | 4.89e-01 | 0.116 |
| 83932 | SPRTN | P11T-E | Human | Esophagus | ESCC | 2.63e-09 | 3.66e-01 | 0.1426 |
| 83932 | SPRTN | P12T-E | Human | Esophagus | ESCC | 6.47e-20 | 3.49e-01 | 0.1122 |
| 83932 | SPRTN | P15T-E | Human | Esophagus | ESCC | 3.17e-13 | 3.24e-01 | 0.1149 |
| 83932 | SPRTN | P16T-E | Human | Esophagus | ESCC | 1.19e-18 | 3.15e-01 | 0.1153 |
| 83932 | SPRTN | P17T-E | Human | Esophagus | ESCC | 1.32e-02 | 1.13e-01 | 0.1278 |
| 83932 | SPRTN | P19T-E | Human | Esophagus | ESCC | 1.30e-02 | 2.84e-01 | 0.1662 |
| 83932 | SPRTN | P20T-E | Human | Esophagus | ESCC | 9.99e-15 | 3.18e-01 | 0.1124 |
| 83932 | SPRTN | P21T-E | Human | Esophagus | ESCC | 1.88e-16 | 3.78e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
| GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
| GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
| GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:190332216 | Esophagus | ESCC | positive regulation of protein modification by small protein conjugation or removal | 99/8552 | 138/18723 | 4.39e-10 | 1.16e-08 | 99 |
| GO:003139816 | Esophagus | ESCC | positive regulation of protein ubiquitination | 82/8552 | 119/18723 | 2.41e-07 | 3.64e-06 | 82 |
| GO:00063012 | Esophagus | ESCC | postreplication repair | 26/8552 | 31/18723 | 1.32e-05 | 1.21e-04 | 26 |
| GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
| GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
| GO:0019985 | Esophagus | ESCC | translesion synthesis | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
| GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
| GO:003139620 | Oral cavity | OSCC | regulation of protein ubiquitination | 143/7305 | 210/18723 | 1.01e-17 | 9.80e-16 | 143 |
| GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
| GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
| GO:00718979 | Oral cavity | OSCC | DNA biosynthetic process | 106/7305 | 180/18723 | 4.86e-08 | 8.95e-07 | 106 |
| GO:00313986 | Oral cavity | OSCC | positive regulation of protein ubiquitination | 75/7305 | 119/18723 | 9.46e-08 | 1.65e-06 | 75 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPRTN | SNV | Missense_Mutation | rs143558208 | c.502C>T | p.Arg168Cys | p.R168C | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| SPRTN | SNV | Missense_Mutation | c.1383N>A | p.Asn461Lys | p.N461K | Q9H040 | protein_coding | tolerated(0.35) | benign(0) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SPRTN | SNV | Missense_Mutation | rs761874937 | c.541N>A | p.Gly181Ser | p.G181S | Q9H040 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SPRTN | SNV | Missense_Mutation | rs145727605 | c.491G>A | p.Arg164Gln | p.R164Q | Q9H040 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SPRTN | SNV | Missense_Mutation | c.1094N>G | p.Ser365Cys | p.S365C | Q9H040 | protein_coding | deleterious(0.02) | possibly_damaging(0.819) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| SPRTN | SNV | Missense_Mutation | c.419N>A | p.Arg140His | p.R140H | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SPRTN | SNV | Missense_Mutation | novel | c.446N>A | p.Ile149Lys | p.I149K | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SPRTN | SNV | Missense_Mutation | c.61N>A | p.Glu21Lys | p.E21K | Q9H040 | protein_coding | tolerated(0.51) | benign(0.001) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SPRTN | SNV | Missense_Mutation | c.419N>A | p.Arg140His | p.R140H | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SPRTN | SNV | Missense_Mutation | novel | c.88N>C | p.Ser30Pro | p.S30P | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |